Have an account? Log in.
I don't have an account.
Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.
Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.